NCT02058251View on ClinicalTrials.gov

Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress

PHASE1CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

January 31, 2017

Study Completion Date

April 30, 2017

Conditions
Alcohol Use Disorders
Interventions
DRUG

Oxytocin

One 40 IU dose of intranasal oxytocin will be self-administered (5 puffs in each nostril) by participants.

DRUG

Placebo

Each participant will self-administer a 40 IU dose of intranasal saline.

Trial Locations (1)

29425

Medical University of South Carolina, Charleston

All Listed Sponsors
lead

Medical University of South Carolina

OTHER

NCT02058251 - Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress | Biotech Hunter | Biotech Hunter